14,764 Shares in DexCom, Inc. (NASDAQ:DXCM) Purchased by Symmetry Partners LLC

Symmetry Partners LLC purchased a new stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 14,764 shares of the medical device company's stock, valued at approximately $990,000.

Other large investors have also recently modified their holdings of the company. Taylor Frigon Capital Management LLC raised its holdings in DexCom by 51.6% in the 3rd quarter. Taylor Frigon Capital Management LLC now owns 32,554 shares of the medical device company's stock worth $2,182,000 after acquiring an additional 11,075 shares during the last quarter. Waters Parkerson & CO. LLC increased its holdings in shares of DexCom by 4.2% in the 2nd quarter. Waters Parkerson & CO. LLC now owns 272,641 shares of the medical device company's stock worth $30,912,000 after purchasing an additional 10,892 shares in the last quarter. Legal & General Group Plc raised its stake in shares of DexCom by 1.7% in the second quarter. Legal & General Group Plc now owns 2,993,049 shares of the medical device company's stock worth $339,352,000 after purchasing an additional 49,076 shares during the last quarter. Factory Mutual Insurance Co. lifted its holdings in shares of DexCom by 136.1% during the third quarter. Factory Mutual Insurance Co. now owns 404,230 shares of the medical device company's stock valued at $27,100,000 after purchasing an additional 233,000 shares in the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund boosted its position in shares of DexCom by 533.1% during the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 36,510 shares of the medical device company's stock valued at $4,140,000 after buying an additional 30,743 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on DXCM shares. Barclays decreased their target price on DexCom from $138.00 to $113.00 and set an "equal weight" rating for the company in a research report on Monday, July 29th. JPMorgan Chase & Co. boosted their price objective on shares of DexCom from $75.00 to $85.00 and gave the company a "neutral" rating in a report on Friday, October 25th. Wells Fargo & Company increased their price objective on shares of DexCom from $80.00 to $90.00 and gave the company an "overweight" rating in a research report on Friday, October 25th. Baird R W downgraded shares of DexCom from a "strong-buy" rating to a "hold" rating in a research report on Friday, July 26th. Finally, Raymond James lowered their price target on DexCom from $115.00 to $99.00 and set a "strong-buy" rating on the stock in a report on Friday, October 25th. Seven research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $104.59.

Insiders Place Their Bets

In other DexCom news, COO Jacob Steven Leach sold 746 shares of the company's stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the transaction, the chief operating officer now directly owns 264,915 shares in the company, valued at $18,318,872.25. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, COO Jacob Steven Leach sold 746 shares of the company's stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the transaction, the chief operating officer now owns 264,915 shares of the company's stock, valued at $18,318,872.25. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Sadie Stern sold 426 shares of DexCom stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the sale, the executive vice president now directly owns 75,451 shares in the company, valued at $5,217,436.65. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 0.30% of the stock is owned by company insiders.

DexCom Stock Performance

Shares of DXCM stock traded down $0.13 during trading hours on Friday, reaching $70.35. 2,735,060 shares of the company traded hands, compared to its average volume of 3,907,564. The firm has a 50-day moving average price of $69.85 and a 200 day moving average price of $95.64. The company has a market cap of $27.48 billion, a P/E ratio of 42.13, a P/E/G ratio of 2.20 and a beta of 1.18. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.